We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”) (NASDAQ: CCXI), in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN).  Under the terms of the merger agreement, the Company’s shareholders will receive $52.00 in cash for each share of ChemoCentryx common stock owned.  The transaction is valued at approximately $3.7 billion.

Weiss Law is investigating whether (i) ChemoCentryx’ s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $52.00 per-share merger consideration adequately compensates ChemoCentryx’ s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, the merger consideration is below the $64.50 median price target set by analysts, and at least one analyst set a price target for the Company of $106 per share, $54.00 above the per-share merger consideration.